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Abstract
Background: Low-grade alimentary lymphoma (LGAL) is characterised by the infiltration of neoplastic T-
lymphocytes, typically in the small intestine. The incidence of LGAL has increased over the last ten years and it is
now the most frequent digestive neoplasia in cats and comprises 60 to 75% of gastrointestinal lymphoma cases.
Given that LGAL shares common clinical, paraclinical and ultrasonographic features with inflammatory bowel
diseases, establishing a diagnosis is challenging. A review was designed to summarise current knowledge of the
pathogenesis, diagnosis, prognosis and treatment of feline LGAL. Electronic searches of PubMed and Science Direct
were carried out without date or language restrictions.
Results: A total of 176 peer-reviewed documents were identified and most of which were published in the last
twenty years. 130 studies were found from the veterinary literature and 46 from the human medicine literature.
Heterogeneity of study designs and outcome measures made meta-analysis inappropriate. The pathophysiology of
feline LGAL still needs to be elucidated, not least the putative roles of infectious agents, environmental factors as
well as genetic events. The most common therapeutic strategy is combination treatment with prednisolone and
chlorambucil, and prolonged remission can often be achieved. Developments in immunohistochemical analysis and
clonality testing have improved the confidence of clinicians in obtaining a correct diagnosis between LGAL and
IBD. The condition shares similarities with some diseases in humans, especially human indolent T-cell
lymphoproliferative disorder of the gastrointestinal tract.
Conclusions: The pathophysiology of feline LGAL still needs to be elucidated and prospective studies as well as
standardisation of therapeutic strategies are needed. A combination of conventional histopathology and
immunohistochemistry remains the current gold-standard test, but clinicians should be cautious about reclassifying
cats previously diagnosed with IBD to lymphoma on the basis of clonality testing. Importantly, feline LGAL could be
considered to be a potential animal model for indolent digestive T-cell lymphoproliferative disorder, a rare
condition in human medicine.
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Background
Lymphoma is a clonal expansion of neoplastic lympho-
cytes in solid organs and is the most common feline
neoplasm [1–7]. Feline lymphomas are usually classified
according to anatomical location, with various types
recognised including mediastinal, multicentric, and
extra-nodal. A final type, alimentary lymphoma (AL) tar-
gets the gastrointestinal tract with variable involvement
of extra-intestinal sites including lymph nodes, liver,
spleen [3, 4, 7, 8]. Not only is this the most common
anatomical form of lymphoma (50 to 75%), it is also the
most common alimentary neoplasia in cats [1–5, 8–19].
Several subtypes of AL can be defined according to
the histological grade (low, intermediate or high), cell
size (small or large) and phenotype (T or B) of the neoplas-
tic lymphocytes [6, 8, 14, 18, 20–23]. Originally, lymphomas
were classified according to the World Health Organization
(WHO) scheme into Enteropathy-Associated T-cell
Lymphoma (EATL) type 1 and 2. Recent studies in human
medicine indicate that EATL consists of two diseases that
are morphologically and genetically distinct. They also dif-
fer in how frequently they are associated with coeliac dis-
ease [24]: EATL type I (80–90% of EATL) is strongly
associated with coeliac disease, has usually a large-cell or
pleomorphic cytology and may express CD30 [24]. EATL
type II (10–20% of EATL) is less frequently associated with
coeliac disease and is characterised by monomorphic popu-
lation with frequent expression of CD56 [24]. EATL type II
has been recently renamed as Monomorphic Epitheliotro-
pic T-cell Lymphoma (MEITL), calling into question its re-
lationship with classical EATL and implying that it might
be best to consider it as a separate entity [25].
The current classification system for this disease has
been defined by Moore et al. and distinguishes two en-
tities [6]: first, “mucosal lymphomas” which are usually
low-grade forms of alimentary lymphoma (LGAL) and
are predominantly of small T-cell type (nuclear diameter
< 2 red cell diameters) that Moore et al. found to match
the WHO entity EATL type II. Second, “transmural
lymphomas”, which are more frequently high-grade ali-
mentary lymphomas (HGAL) and are composed of small
or large cells that can be of B- or T-cell type. Trans-
mural intermediate to large-sized T-cell lymphomas
would match the WHO entity EATL type I for Moore et
al. When of large T-cell type, these lymphomas are
mostly Large Granular Lymphocytic Lymphomas
(LGLL) and express the cytotoxic granule protein, gran-
zyme B. LGLL is less frequent, but the most aggressive
subform of AL and can be considered as a separate
histological sub-classification of AL with LGAL and
HGAL [8, 26, 27].
LGAL may be the most common subtype in cats,
representing 60 to 75% of AL [18–20]. However, the real
incidence is not accurate since it is based upon a few
small sample studies. Moreover, for unknown reasons, it
appears to be an emerging entity with an increasing inci-
dence over the last ten years [8, 28]. The aim of this re-
view is to provide an overview of current knowledge
regarding the aetiology, clinical and biological presenta-
tion, diagnosis, treatment and prognosis of LGAL. Com-
parisons of this condition with the rare human disease,
indolent T-cell lymphoproliferative disorder (LPD) of
the gastrointestinal tract, will also be highlighted.
Methods
Electronic searches of PubMed and Science Direct were
carried out without date or language restrictions. A total
of 176 peer-reviewed documents were identified and
most of which were published in the last twenty years.
130 studies were found from the veterinary literature
and 46 from the human medicine literature. Heterogen-
eity of study designs and outcome measures made
meta-analysis inappropriate.
Results
Aetiopathogenesis
The aetiopathogenesis of feline LGAL is poorly under-
stood. Several factors have been implicated as possible
causes, but their involvement remains inconclusive, par-
ticularly considering the relationship with the AL histo-
logical grade and phenotype [14].
Feline retroviruses
An infectious aetiology has been suggested because the risk
of developing AL is greater in cats infected by feline retrovi-
ruses (feline leukaemia virus [FeLV] or feline immunodefi-
ciency virus [FIV]). However, this hypothesis has been
challenged on account of the fact that most lymphocytic
cancers in all species are non-retroviral-associated [29].
FeLV infects the lymphoid tissue, intestine and bone
marrow [3], and is suspected to be a major risk factor in
development of leukaemia and lymphoma in cats, par-
ticularly T-cell lymphoma with a mediastinal location
[30, 31]. Immunohistochemical studies have identified
that 50 to 70% of all feline lymphomas are positive for
FeLV [3, 7, 13, 32, 33] and its presence is associated with
poor prognosis in all lymphoma subtypes [2, 34]. The
exact mechanisms by which FeLV causes neoplastic
transformation are not known but could be related to
virus genome insertion, resulting in modulation of
neighbouring oncogenic or tumour suppressor gene ex-
pression [30, 35]. Further, in contrast to multicentric
lymphoma, the exact role of FeLV in development of AL
is also unclear since it is inconsistently identified in AL
cases [34, 36, 37], and many forms of lymphoma, includ-
ing AL, can effectively develop without exposure to
FeLV in pathogen-free cats [2, 10]. Over the past
30 years, circulating FeLV antigen has been observed in
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2 to 30% of cats with AL [3, 20, 36–38] but, more re-
cently, most AL cases do not have circulating FeLV anti-
gen [13]. One possible explanation for this is the success
of widespread implementation of test and vaccination
programmes, which have helped to decrease FeLV preva-
lence in cats [2, 5, 20, 39].
Using immunohistochemistry (IHC), only 3% of AL tu-
mours are positive for FeLV [20, 37, 40] although, in one
study involving 25 cats with AL, alimentary lymphoma
provirus sequences were detected in approximately 1/3
of B-cell AL and almost 2/3 of T-cell AL [36]. These lat-
ter findings suggest that FeLV may be present in a latent
or replication-defective form in some cases [36, 40]. In
contrast, no provirus form of FeLV was detected in an-
other study involving 32 AL cases, 30 of which were
FeLV-antigen-negative [38]. The discrepancies between
both studies could be due to variability in assay sensitiv-
ity, with the higher prevalence of FeLV provirus detec-
tion in the first study possibly result of use of a
highly-sensitive semi-nested PCR assay [36]. Additional
epidemiological, functional and highly-sensitive molecu-
lar analyses are therefore required to clarify the role that
FeLV plays in AL. In particular, it would be helpful to
clarify the association between the presence of FeLV and
different histological grades of AL, especially LGAL
given its increasing prevalence.
Like human (HIV) and simian (SIV) immunodefi-
ciency viruses [41–43], FIV can induce indirect immune
dysregulation, resulting in partial loss of antitumoral im-
munity and ultimately promoting tumour development
[3, 44, 45]. Studies have shown that FIV infection may
increase the risk of developing various types of lymph-
oma, including AL [7, 14, 34, 46]. In addition, compo-
nents of the FIV genome were detected in tissues from 7
of 8 AL that had developed in FIV-positive cats [47], 4
and 3 of which were B- and T-lymphoma, respectively.
Various parts of the gastrointestinal tract were affected,
and there was mesenteric lymph node involvement in 3
cats. However, unfortunately histological grade was not
determined.
A final virus that has been implicated as an aetiological
agent is the panlymphotropic Felis catus gammaherpes-
virus 1 (FcaGHV1), and this virus is known to infect at
least one quarter of cats. A possible role is plausible
given the detection of two human gammaherpesviruses
(Epstein-Barr and Kaposi’s sarcoma-associated viruses)
in some lymphoma cases [48, 49]. However, in one
study, neither detection of FcaGHV1 DNA nor whole
blood virus load was related to a diagnosis of lymphoma
[50]. That said, the presence of circulating FcaGHV1
DNA was associated with significantly shorter survival
compared with FcaGHV1 qPCR negative cases [50]. A
limitation of this study was the fact that the criteria used
to recruit lymphoma cases excluded lymphocytic
low-grade gastrointestinal lymphoma and, as a conse-
quence, further studies are required.
Bacterial infections
Over the last two decades, bacterial mucosal colonisa-
tion, particularly involving argyrophilic organisms such
as Helicobacter spp., has been highlighted as a potential
oncogenic factor in feline gastric cancer as a result of
chronic antigenic stimulation [51, 52]. Helicobacter pyl-
ori infection is strongly associated with development of
adenocarcinoma and mucosa-associated lymphoid tissue
(MALT) lymphoma in humans [53, 54]. The gastric mu-
cosa of dogs is often colonised by non-Helicobacter pyl-
ori helicobacters. Although their pathogenic significance
in dogs is poorly understood, there is evidence of Helico-
bacter spp. infection in laboratory beagle dogs resulting
in gastric lymphoid follicle formation that is considered
a precursor of MALT lymphoma in humans [55].
Gastric Helicobacter heilmannii (Hhe) strains were re-
ported to promote feline gastric lymphoma in one study
involving 47 cats, where respectively 14 out of 16 and 2
out of 16 lymphoblastic and lymphocytic lymphomas
were positive for Hhe organisms (especially the Hhe2
and Hhe 4 strains) [52]. Amongst a population of 33
low-grade T-cell epitheliotropic small intestinal lymph-
omas, mucosa-invasive bacteria and serosal colonisation
have been identified in 18% and 11% of cases, respect-
ively. In comparison, of the 17 high grade small intes-
tinal lymphomas, 14 (82%) were associated with
mucosal-invasive bacteria, serosal colonisation was evi-
dent in 10 (57%), and intravascular bacteria were ob-
served in 5 (29%) [56]. In contrast, bacteria were not
detected in any of the cases of LGAL [56]. However, it
remains unclear whether invasive bacteria might trigger
the development of AL or are instead opportunistically
colonising the damaged mucosa after AL has developed
[56]. Further prospective studies are required to estab-
lish whether lymphomatous mucosa could be permissive
for bacterial colonisation in this context.
Chronic inflammation
It is suggested that chronic inflammation can increase
the risk of developing AL, not least given that concur-
rent inflammatory bowel disease (IBD) has been de-
scribed in up to 60% of AL cases [57–61], with many
hypothesising that IBD may precede or promote digest-
ive neoplasia [20, 38, 59, 62–66]. It has also been sug-
gested that certain forms of human coeliac disease
might actually represent low-grade intraepithelial T-cell
malignant lymphoma rather than being a reactive T-cell
proliferation [67, 68], and this has also been suggested
for feline lymphoplasmacytic enteritis [20].
However, to date, there is no published veterinary evi-
dence demonstrating the development of AL subsequent
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to chronic intestinal inflammation. In one recent study,
MDR1 gene expression (MDR1, which encodes an efflux
pump membrane protein) and cyclo-oxygenase 2
(COX2) were assessed in cats with chronic enterop-
athies, and were found to be greater in cats with LGAL
than in cats with IBD [63]. It is not possible to determine
if increased MDR1 expression plays a role in the aetio-
pathogenesis of feline IBD and LGAL but these results
could explain the necessity of a more aggressive therapy in
the lymphoma [63]. However, human patients with IBD
show reduced expression of MDR1 in the colon and over-
expression of COX2 may be associated with cell prolifera-
tion and angiogenesis [69, 70].
Other factors
Chronic cigarette smoke exposure and geographic fac-
tors have been suggested to promote AL but reported
cases were not further subdivided based upon grade [8,
11, 14, 71]. Dietary factors have also been implicated in
the development of LGAL, although this is controversial,
because there is no direct evidence for it [11, 29]. Fur-
ther studies are required to clarify the role played by all
such factors.
Clinical presentation
Signalment
LGAL usually affects ageing cats (median age 13 years)
[8, 28, 59, 60, 72–74], and some studies have suggested
that male cats are predisposed [4, 11, 20, 40, 60]. The
role of breed is less clear; to date, no specific association
has consistently been found between breed and LGAL in
cats, although domestic shorthair and Siamese are
over-represented in some studies of AL, [59, 60, 73].
Clinical signs
LGAL has a chronic progressive course over weeks or
months, with clinical signs (in order of frequency) includ-
ing: weight loss (80–90%), vomiting (70–80%), anorexia
(60–70%), diarrhoea (50–65%), and to a lesser extent, ic-
terus, splenomegaly, polydipsia/polyuria and lethargy [2, 3,
7, 8, 14, 38, 59, 61, 62, 72, 75–78]. These signs are not
pathognomonic and overlap with other alimentary and in-
deed non-alimentary diseases. Therefore, differential diag-
nosis requires excluding metabolic diseases,
endocrinopathies, inflammatory diseases such as feline
triaditis, infectious processes, and other neoplastic dis-
eases. Given the fact that LGAL mainly affects older cats,
potential comorbidities may complicate the clinical fea-
tures. However, the major diagnostic challenge faced by
clinicians is distinguishing LGAL from IBD (see Table 4)
and other forms of AL. It is suggested that abdominal pal-
pation can help because, in contrast to LGAL, aggressive
forms of AL are more commonly associated with abdom-
inal mass lesions, lymphadenomegaly, peritonitis or ascites
[1, 3, 7, 77]. Nevertheless, the findings of abdominal palpa-
tion do not reliably distinguish IBD and AL [2, 8, 17].
When LGAL is involved, thickened bowel loops may be
identified, although this can also be a non-specific finding
[8, 15]. Finally, it should be noted that abdominal palpa-
tion may also be normal in cats with LGAL [79].
Gastrointestinal location
In LGAL, lesions are diffuse rather than localised, and
can be focal or multiple, affecting any component of the
gastrointestinal tract including the stomach, small intes-
tine or large intestine as well as the mesenteric lymph
nodes, liver or spleen [2, 11, 14, 38, 59, 73]. Although all
sections of the gastrointestinal tract can be affected by
LGAL, the most common sites include the jejunum and
the ileum, followed by the duodenum [6, 20, 59]. Gastric
involvement is uncommon for this type of AL (see
Table 1) [1, 6, 15, 20, 59, 74, 80, 81].
Diagnosis
As mentioned above, the clinical signs of LGAL are not
pathognomonic making diagnosis challenging. During
diagnostic investigations, metabolic diseases, endocrinopa-
thies, infectious diseases, chronic cholangitis, pancreatitis,
and exocrine pancreatic insufficiency should first be ruled
out using clinicopathological testing and diagnostic im-
aging [79, 82]. Thereafter, LGAL should be differentiated
from other gastrointestinal tract diseases such as
food-responsive enteropathy (FRE) and IBD. Whilst diet-
ary trials can usually eliminate FRE as a possible cause,
distinguishing LGAL from IBD (such as lymphoplasmacy-
tic enteritis [LPE] or eosinophilic enteritis [EE]) is more
challenging because clinical signs, results of clinical path-
ology, diagnostic imaging findings, and even histological
features can overlap [8, 11, 15, 60, 83–85]. Ultimately,
more advanced diagnostic techniques such as immunohis-
tochemistry and PCR for Antigen Receptor Rearrange-
ment (PARR) are required to confirm the diagnosis.
Paraclinical data
Extensive tests are often required to distinguish LGAL
from other diseases, and a typical investigation would in-
volve haematology, serum biochemistry, urine and faecal
analyses, total thyroxine concentration, diagnostic im-
aging and intestinal biopsies. Cats should also be tested
Table 1 Segments of the gastrointestinal tract affected by low-
grade alimentary lymphoma (LGAL)
Segments of the small intestine Prevalence Study
Duodenum 83% (10/12) Lingard et al. [59]
Jejunum 100% (15/15) Lingard et al. [59]
86% (43/50) Fondacaro et al. [20]
Ileum and ileocaecocolic junction 93% (13/14) Lingard et al. [59]
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for FeLV and FIV, given the previously-reported associa-
tions with AL [75], and serum folate and cobalamin con-
centrations should be measured to determine the
presence of malabsorption.
Biomarkers
Biomarkers that have been used in cases of AL are sum-
marised in Table 2. To the authors’ knowledge, no study
has yet demonstrated the ability of paraclinical data to
differentiate LGAL from IBD. However, failure to recog-
nise and correct hypocobalaminaemia is known to delay
clinical recovery, even when specific therapy for AL or
IBD is instituted [82, 86]. Hypoalbuminaemia is reported
in 70% of cats with AL, 49% with LGAL, and 77% with
IBD respectively [20, 87]. The reason why hypoalbumi-
naemia is less common in LGAL, compared with other
types of AL, is not known but might reflect the fact that
mucosal integrity is preserved until later in the disease
process [2, 8, 14]. In dogs, cytokine IL6 suppresses albu-
min synthesis and may be released by neoplastic cells
[88], and this might contribute to the progressive
hypoalbuminaemia observed in AL [88, 89]. Previous
studies have documented the prevalence of hypocobala-
minaemia in cats with gastrointestinal disease, with ap-
proximately a third of IBD cases being affected [82, 83,
87, 90–93]. Between 50 and 80% of LGAL are associated
with hypocobalaminaemia (Ref.: > 290 ng/L) [2, 8, 11,
72, 75, 83, 87, 90, 94]. Not only is hypocobalaminae-
mia of diagnostic and prognostic significance, it can
also exacerbate signs of diarrhoea, vomiting, anorexia,
and weight loss, as well as causing weakness when
severe.
Ultrasonography
Abdominal ultrasonography allows reliable detection of
focal or diffuse thickening as well as loss of the normal
layered appearance of the gastrointestinal wall (Fig. 1)
[15, 95]. In addition, this imaging modality may reveal
other LGAL-associated lesions, such as mesenteric lym-
phadenomegaly, hepatomegaly and splenomegaly [2].
The most common ultrasonographic finding is a diffuse
thickening of muscular layer in the small bowel, and this
characteristic is observed in 50–80% of cases [15, 59, 77,
95–97]. Unfortunately, given that this is also commonly
observed in feline patients with IBD [98], ultrasono-
graphic distinction between LGAL and IBD is not possible
(Fig. 2 and Table 3). For example, in one study involving
22 cats with FRE, 17 with IBD and 17 with AL, there were
no significant differences in ultrasonographic findings be-
tween the three groups [82]. Moreover, ultrasonography is
less sensitive for the detection of small lesions of the gastro-
intestinal tract than is endoscopy [2]. Therefore, LGAL can
never be excluded on the basis of a normal ultrasono-
graphic examination and histological analysis is always re-
quired to make a definitive diagnosis [2, 95].
Thickening of the gastrointestinal wall is the most
common lesion observed in AL (Fig. 2) [2]. However, al-
though reference measurements for wall thickness have
been reported in cats, clear diagnostic cut-points for ei-
ther LGAL or IBD have not been reported [95, 99]. Po-
tentially of more utility, is the identification of a
thickened muscularis propria, which might be twice as
thick as that seen in healthy cats [15]. Typically, the ra-
tio of muscularis width to submucosal width in calcu-
lated, with measurements ≥0.5 being considered
abnormal [15, 95]. This feature is reported to be com-
mon in feline LGAL [15, 82, 95], although it is not
pathognomic because it is also reported in IBD [15, 82],
particularly in eosinophilic enteritis (EE) [100]. That
said, older cats with ultrasonographic evidence of mus-
cularis propria thickening are more likely to have AL
versus IBD [78, 95].
Table 2 Description and prevalence of paraclinical data abnormalities reported in alimentary lymphoma (AL)
Data Description Paraclinical data AL
Cases Prevalence
Albumin Biomarker of gastrointestinal
protein loss [87]
Decreased [87] LGAL 49% (21/43) [20]
Cobalamin (Vitamin B12) Biomarker of
absorption [8, 72, 83, 92, 170]
Decreased [87] LGAL 50–80% [2, 8, 11, 72, 75, 83, 87, 90, 94]
AL 35,3% (6/17) whose 12 LGAL [77]
Folate (Vitamin B9) Biomarker of absorption
and dysbiosis [8, 72, 83, 86, 92, 170]
Increased
or decreased [82, 87]
LGAL 37% (10/27) > 21.6 ng/ml [72]
AL 31% (4/13) < 9.7 ng/ml [83, 87]
Lactate dehydrogenase (LDH) Biomarker of
cellular necrosis [171]
Increased [172] LGAL 47% (9/19) [172]
Fecal a1 proteinase inhibitor
concentration
Biomarker of gastrointestinal
protein loss [87]
Increased [87] AL 100% (8/8) [87]
Total serum protein Biomarker of gastrointestinal
protein loss [87]
Decreased [87] AL 100% (7/7) [87]
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Enlarged mesenteric lymph nodes are another com-
mon ultrasonographic finding [8, 82, 95, 101, 102]. In
one retrospective study, mesenteric lymphadenomegaly
was reported in 6 out of 10 AL cases, and 2 out of 12
IBD cases [77]. Mesenteric lymph node thickness can
vary, with the average being 4 to 6 mm for jejunal lymph
nodes and 5 mm for ileo-caecal lymph nodes [15, 99]. In
AL, changes in lymph node size can be highly variable,
ranging from minimal to markedly enlarged, although,
in recent studies, moderate enlargement is most likely
[2, 59, 77, 95, 96]. Mesenteric lymph node enlargement
was reported in 17 LGAL cases in one study, with a
mean diameter of 15.9 mm (range 6.5–30 mm) [59]. In a
more recent study, colic lymph nodes in LGAL cats were
reported to be 1.6-fold larger in size than those from
healthy cats whereas jejunal lymph node hypertrophy
was not systematically associated with LGAL [15].
Endoscopy and coeliotomy
Gastrointestinal endoscopy is an important investigative
tool in feline gastroenterology providing the ability to
access the stomach, duodenum, distal ileum and colon,
as well as allowing direct visualisation of the mucosa
[75, 103]. Experienced endoscopists can often reach the
proximal jejunum [103, 104]. It is a minimally invasive
and rapid technique allowing macroscopic lesions to be
described and multiple intestinal biopsy samples to be
collected, albeit exclusively from mucosa or submucosa
[15, 20, 72, 105]. Mucosal lesions that cannot be charac-
terised by ultrasonographic examination may be identi-
fied by endoscopy [75, 106, 107]. Macroscopic
differentiation between inflammatory lesions (conges-
tion, oedema, mucosal fibrosis) and LGAL lesions is not
possible by endoscopic examination [20, 107]. In
addition, the jejunum and the proximal part of the
ileum, which are the most frequent locations of LGAL,
are often not accessible by endoscopy [105]. Evans et al.
suggested exploratory cœliotomy may be preferable to
endoscopy [77]. However, in their study involving 10 AL
and 12 IBD, duodenal assessment was limited in half the
cats and biopsies were performed blindly in 8 of the cats
which might have contributed to the poor sensitivity of
endoscopic biopsies. By obtaining endoscopic specimens
of the jejunum and ileum, laparoscopy may improve the
Fig. 1 Ultrasonographic appearance of normal intestine (a) and low-grade alimentary lymphoma (LGAL) (b), longitudinal section. Note the
marked thickening of the muscularis propria in the patient with LGAL (b) compared to a cat with a normal jejunal layering (a). The full thickness
of both loops (between calipers) is within normal limits: normal jejunum 2.7 mm and LGAL jejunum 2.5 mm. Scale: 10 mm
Fig. 2 Ultrasonographic images depicting a diffuse intestinal wall thickening in low-grade alimentary lymphoma (LGAL) (a) and inflammatory
bowel disease (IBD) (b). a Cat with advanced LGAL (duodenum): a moderate thickening of the muscularis propria is observed. Full-thickness
(between calipers): 3.7 mm. b Cat with IBD, eosinophilic enteritis (small intestine): note the similar ultrasonographic appearance of the intestine
compared to LGAL aspect. Full thickness (between calipers): 3.9 mm. Scale: 10 mm
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diagnostic sensitivity and may therefore be a minimally
invasive alternative to exploratory cœliotomy [77].
Although exploratory cœliotomy is more invasive than
endoscopy, all segments can be inspected, full-thickness
biopsies (mucosa, submucosa, muscularis and serosa)
can be taken from various sites (stomach, duodenum, je-
junum and ileum) [3, 4, 11, 15, 59, 75], and biopsies of
other organs (e.g. peripheral lymph nodes, liver, and
pancreas) if indicated [99]. The technique is generally
safe with post-operative complications being uncommon
[108]. Indeed, there was no clinical evidence of postop-
erative leakage from the biopsy sites and a low incidence
of post-operative complications in published reports in-
volving 70 AL cases where full-thickness gastrointestinal
biopsies were taken [75, 76]. Unfortunately, regardless of
method used for biopsy sampling, diagnosis remains
challenging because of the frequent lack of gross
changes in cases of LGAL. Multiple systematic biopsies
of all the digestive areas are therefore recommended
[14, 61, 79, 107].
Cytology and histology
Both cytological and histological assessment can be used
to aid in the diagnosis of AL in cats. Whilst cytology
samples can be easier to collect, results may be unreli-
able, particularly for LGAL, where the rate of
false-negatives for mesenteric lymph nodes can reach
50% [59, 60, 75, 107, 109–111]. Few intra-abdominal
lymph node cytology results are positive for LGAL, pos-
sibly because the neoplastic lymphocyte population
mainly comprises small lymphocytes, which would not
be considered to be unusual in a lymph node [60]. Con-
versely, aspiration cytology of focal intestinal wall masses
or enlarged mesenteric lymph nodes are considered ad-
equate to diagnose HGAL or LGLL [82, 107].
Histological examination of the small intestine is import-
ant in establishing a diagnosis of AL [1, 28, 97, 101, 109,
112], and it is advisable to define clinical features according
to the guidelines of the World Small Animal Veterinary As-
sociation Gastrointestinal Standardization Group [104,
113]. LGAL lesions are characterised by an infiltrate of neo-
plastic lymphocytes of small-to-intermediate size and in-
volving the epithelium and lamina propria of the villus
(Fig. 3); infiltration of the submucosa and muscularis is also
frequent [6, 58, 60, 75]. Since the MALT includes the lar-
gest population of lymphoid and accessory immune cells in
the gastrointestinal tract, it is the primary site of neoplastic
proliferation [6, 114]. Differentiation between inflammatory
and neoplastic infiltrates is often challenging because the
histological features of LGAL and IBD (especially lympho-
plasmacytic enteritis) can be similar (Fig. 3) [58, 82]. How-
ever, amongst the criteria to distinguish LGAL from IBD,
epitheliotropism, defined as the characteristic homing of
neoplastic T-cells to the mucosal epithelium [60], is argu-
ably most important, and in particular the presence of
intraepithelial nests and plaques [6, 19, 60, 61, 79]. An
intraepithelial nest is defined as 5 or more small
T-lymphocytes clustered within the villous epithelium, and
an intraepithelial plaque as 5 or more adjacent epithelial
cells obscured by infiltrates of small T-lymphocytes [61,
85]. Mild cases may be limited to purely intra-mucosal infil-
tration of small T-cells into the epithelium layer [60]. Two
studies found that the majority of the intraepithelial lym-
phocytes in healthy and specific pathogen-free cats were
CD3+ [114, 115]. Whilst epitheliotropism is suggestive of
LGAL rather than IBD, its absence cannot be used to ex-
clude the condition because it is not observed in all digest-
ive T-cell lymphomas [61].
Therefore, intraepithelial lymphocytes are an import-
ant cell population to study during histological assess-
ment of feline gastrointestinal biopsies, and are usually
of T-cell phenotype [6, 60]. In healthy cats, there are
many more intraepithelial lymphocytes in the villous
epithelium than in the crypt epithelium in all regions of
the small intestine, and this is also for cats with IBD, AL,
Table 3 Comparison of ultrasonographic features observed in
low-grade alimentary lymphoma (LGAL) and inflammatory
bowel disease (IBD)
Ultrasonographic
parameter
LGAL IBD
Gastrointestinal
wall thickness
Muscularis propria
frequently thickened
[8, 15, 59, 82, 95, 101]
Muscularis propria
frequently thickened
in eosinophilic enteritis
(EE), possibly increased
in lymphoplasmacytic
enteritis (LPE)
[15, 78, 82, 84, 95, 101]
Size of
mesenteric
lymph nodes
Lymphadenomegaly
(> 5 mm) frequent
but not systematic
[8, 82, 95, 101, 102]
Lymphadenomegaly
frequent but not
systematic [78, 82, 95]
Gastrointestinal
intramural
masses
Rare but possible [75] Rare but possible [75]
Stratification
and architecture
Normal [8, 59]
to modified [61, 82, 101]
Normal to modified
[82, 95]
Motility Normal to reduced [95] Normal to reduced [95]
Intussusception Rare but possible [2, 75] Very rare but possible
[2, 75]
Liver appearance Hypo- or
hyperechogenicity
possible, lobular
pattern if
liver involved [2]
Non specific [2]
Pancreas NA Changes suggestive
of pancreatitis
(pancreatic
hypoechogenicity,
peripancreatic
hyperechoic fat)
[78, 173]
NA not available
Paulin et al. BMC Veterinary Research  (2018) 14:306 Page 7 of 19
and epitheliotropic intestinal malignant lymphoma (EIL)
[60, 115]. However, there are usually markedly more
intraepithelial lymphocytes in cats with EIL than either
healthy cats or cats with IBD [60]. Further, the common
occurrence of epitheliotropism in small intestinal T-cell
lymphoma has been described [6, 57, 60], with one study
demonstrating that 62% of mucosal T-cell lymphoma of
small-cell type had characteristics of EIL. Epitheliotropism
is also an important feature of HGAL, occurring in 58% of
transmural T-cell lymphoma and in some T-cell LGLL of
the small intestine [6, 114, 116].
Inter-observer variability can occur and histology must
be correlated with clinical status and outcome [117,
118]. Moreover, a discrepancy between the perceived
lower number of intraepithelial lymphocytes based on
HE stains and the greater number of intraepithelial lym-
phocytes based on CD3 stain has been noted, possibly
because of the difficulty in differentiating them from
enterocytes in HE-stained sections [60, 115]. In addition
to the described changes in lymphocyte populations,
concurrent histological abnormalities in neoplastic re-
gions include lymphoid microabscesses in the mucosal
epithelium, villous blunting and fusion, increased plasma
cell infiltrate within the lamina propria and eosinophil
infiltrate into the lamina propria [60].
Immunohistochemistry
Immunohistochemistry has become an increasingly im-
portant molecular technique to improve the diagnosis of
AL, especially to aid in the differentiation of LGAL and
IBD [10, 15, 62, 77, 103, 106, 119]. Since it can often be
performed on formalin-fixed and paraffin-embedded
(FFPE) biopsies, it must be readily performed as a com-
plementary technique to standard histological examin-
ation. With IHC, specific monoclonal antibodies are
applied that recognise antigenic determinants (epitopes),
thereby enabling microscopic detection of differentiation
and proliferation biomarkers [10, 62, 111]. The most
commonly-used antibodies include anti-CD3 to detect
T-lymphocytes [6, 10, 39, 60–62, 79, 120], coupled with
anti-CD79a, anti-CD20 and anti-BLA36 to detect
B-lymphocytes [39, 60–62, 72, 103], MAC387 highlights
macrophages [10, 62], and anti-CD57 is used to detect
natural killer (NK) cells [6]. Moreover, the percentage of
proliferating cells can also be determined immunohisto-
chemically by detecting Ki67 expression [10]. Ki67 is
expressed in the nucleus during all phases of the cell
division cycle, with its concentration increasing during
the cell cycle, becoming maximal expression in M-phase
and then totally disappearing after mitosis [10, 121, 122].
However, whilst useful, the authors are not aware of any
threshold value that reliably discriminates either between
the different feline AL subtypes, or IBD [10]. Other spe-
cific feline antibodies (anti-CD4, anti-CD8α, anti-CD8β)
can be used to detect additional epitopes and define the
immunophenotype of lymphomas, but their routine clin-
ical application is limited by the fact that formalin-fixed
samples cannot be used as frozen sections are required
[10].
LGAL is of T-cell phenotype in 90% of the cases,
staining positively with anti-CD3 antibody (Fig. 4), with
a B-cell phenotype observed in the remaining 10% of
cases [6, 8, 10, 11, 58, 63, 75, 97]. However, there is in-
creasing evidence that some human and canine T-cell
lymphomas co-express the B-cell marker CD20 [123–
125]. In a three-case series reported by Nolan and Kiu-
pel (2018), the majority of neoplastic CD3+ lymphocytes
expressed CD20 but not Pax5. In all cases, PARR testing
demonstrated clonal rearrangement of the T-cell recep-
tor gamma gene, suggesting a diagnosis of CD3+, CD20+
enteropathy-associated T-cell lymphoma, large cell type
[80]. This explains why the PARR is most suited to de-
tecting clonally expanded lymphocyte populations, ra-
ther than determining phenotype [85].
Moreover, human peripheral T-cell lymphoma may ex-
hibit aberrant expression of CD20 [123], and a subset of
Fig. 3 Histological features of low-grade alimentary lymphoma (LGAL) and plasmacytic enteritis (haematoxylin-eosin-staining, 400X). a LGAL:
monomorphic dense infiltrate of small lymphocytic cells with discrete nuclear atypia; some plasma cells are present. b Plasmacytic enteritis: less
compact infiltrate of small lymphocytes with dense nucleus; more plasma cells are present
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T-lymphocytes with low-expression of CD20 (known as
CD20dim T-lymphocytes) has been detected in normal
peripheral human blood [126]. It is not currently known
whether CD20 expression in canine lymphoma reflects
aberrant expression or whether the neoplastic lympho-
cytes originated from a subpopulation of normal
CD20dim T-cells. Finally, in a recent study involving
40 T-cell AL, 5 B-cell AL and 8 IBD, T-cell lymphomas
in particular were characterised by a high percentage of
Bcl-2 (B-cell lymphoma gene 2) labelled cells, whilst
B-cell lymphomas varied more widely in the number of
positively-labelled cells [19]. Further studies are required
to clarify the exact phenotypes of LGAL, although this
has been hampered by the limited number of antibodies
available for IHC studies.
Clonality testing
In conjunction with other diagnostic techniques, clonal-
ity analyses have been increasingly used in veterinary
pathology to differentiate reactive and neoplastic lymph-
oid proliferations, for example differentiating IBD from
LGAL [6, 112, 127]. This diagnostic tool was first re-
ported for feline intestinal T-cell lymphoma by Moore et
al. in 2005 [57], with the most commonly reported ap-
proach being PARR. This technique is based on PCR tar-
geting of the CDR3 region of T-cell receptor gamma
(TCRγ) for T-cells and immunoglobulin heavy chain
genes (IGH) for B-cells [57, 58, 85, 95, 111, 127–129],
and can detect clonally expanded lymphocyte popula-
tions. However, PARR cannot determine lymphocyte
phenotype and, therefore, it complements rather than
replaces the use of immunohistochemistry. This is be-
cause neoplastic lymphocytes may have clonal rearrange-
ment of either or both the T- or B-cell antigen receptor
genes, regardless of phenotype [57, 61, 85, 130]. For ex-
ample, cases of mucosal T-cell lymphoma of small cell
type may show clonal rearrangement of the IGH gene.
This is termed cross-lineage rearrangement and can be
an effect of malignant transformation but causes remain
to be elucidated [61, 85, 131, 132]. Cross-lineage re-
arrangement has previously been reported in both hu-
man and canine T-cell malignancies [133, 134].
More than 90% of LGAL exhibit a clonal or oligoclonal
TCRγ gene rearrangement, whereas IBD usually displays a
polyclonal pattern [6, 57]. Moreover, the diagnostic sensi-
tivity and specificity of PCR-based clonality assays for rou-
tine diagnosis of feline TCRγ gene rearrangement are
currently close to 90% [6, 57, 128, 135]. As a result, Sabat-
tini et al. recommended the assessment of clonality in
duodenal endoscopic biopsies to increase the detection
sensitivity to distinguish between LGAL and IBD [112].
Taken together, these data suggest that clonality testing
should be integrated in the routine diagnosis work-up of
LGAL. Initially developed on frozen samples, molecular
clonality testing can now be performed on formalin-fixed
and paraffin-embedded (FFPE)-derived samples [136],
making this assay more easily accessible. The average sen-
sitivity for diagnosis of feline AL was highest (0.83), inter-
mediate (0.78), and lowest (0.72) for using histology and
IHC and clonality, histology and IHC, and histology alone,
respectively [61, 107].
Even where there is agreement between histological
findings and clonality analysis, clinical, morphological,
and immunophenotypic data should ideally be integrated
with clonality analysis in order to reduce the chances of
a misdiagnosis [6, 19, 61, 82, 127]. Cross-lineage re-
arrangement of the IGH gene was detected in at least
9% of cases diagnosed as T-cell AL [85, 129]. Moreover,
a polyclonal rearrangement of the TCRγ gene can also
be observed. Reasons for this pattern include the pres-
ence of inflammatory T-cell infiltrates within the evalu-
ated tissues which then mask the clonal T-cell
population, or the exclusive amplification of the TCRγ
gene of resident or inflammatory T-cell populations of
the intestine [57, 85]. Conversely, detection of a clonal
lymphocyte population is not always indicative of
Fig. 4 Histological (a) (haematoxylin-eosin-staining, 200X) and immunohistochemical (b) (anti-CD3, immunoperoxydase, 200X) features of low-
grade alimentary lymphoma (LGAL) showing dense infiltration of the lamina propria composed of a mixture of small CD3+ T lymphocytes and
plasma cells, with epitheliotropism (small intestine biopsies)
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neoplasia, since this can sometimes be seen as a re-
sponse to pathogens and concurrent malignancies [61,
85]. In the study of Kiupel et al., involving 47 AL and 16
IBD, one case had clonal population of B-cells and a
final diagnosis of IBD was made, when histomorphology
and immunophenotyping results were taken into consid-
eration. Amongst ten cats with an oligoclonal population
of T-cells, one case was diagnosed as IBD [61]. More-
over, high percentage of clonality has been associated
with marked inflammatory process in humans [137].
That said, whilst clonality testing can provide add-
itional information on a particular case, the use in diag-
nosis has not yet been critically reviewed and properly
validated. Therefore, for now, clinicians should be cau-
tious about reclassifying cats previously diagnosed with
IBD to lymphoma on the basis of PARR, and a combin-
ation of conventional histopathology and immunohisto-
chemistry (IHC) remains the current gold-standard test.
Staging
To our knowledge, the staging criteria classically defined
for other types of lymphoma cannot be reliably used to
classify LGAL [3, 5, 20, 38].
Distinguishing low-grade alimentary lymphoma
from inflammatory bowel disease
As discussed above, a major challenge of the clinician is
to distinguish LGAL from IBD given that their clinical
presentations overlap. Table 4 provides a summary of
Table 4 Comparison of aetiology, epidemiology, and clinical features in cats with low-grade alimentary lymphoma (LGAL) and
inflammatory bowel diseases (IBD)
LGAL IBD
Aetiology Currently unknown Currently unknown, multifactorial
disease, though many factors implicated
including genetic factors and
enteric bacteria or protozoa [3, 11, 52, 63]
Age Mainly older cats [4] Any age [63, 78, 79, 82]
Breed No breed predisposition [59] Domestic shorthair and longhair,
Persian, Siamese predisposed [63, 78, 79, 87]
Gastrointestinal locations Any but jejunum and ileum
most common (90%) [58, 59, 119]
Any but duodenum and
ileum most common (70–90%) [58, 59, 119]
Clinical signs Weight loss, vomiting,
anorexia, diarrhea, lethargy [8, 63, 79]
Weight loss, vomiting, anorexia,
diarrhea, lethargy [8, 63, 79]
Biomarkers
Albumin Decreased (49%) Decreased (77%) [87]
Total proteins NA Increased (18%) [78]
Cobalamin Decreased (50–80%)
[2, 8, 11, 75, 82, 83, 87, 90, 94]
Decreased (18–47%) [78, 82, 87]
Folate Increased (37%) [72] Increased (22%) [87]
LDH Increased (47%) [172] Increased (26%) [172]
ALP and ALT NA Increased (23%) [78]
fPLI NA Increased (18%) [78]
Phosphate NA Decreased (47%) [78]
Ultrasonography Muscularis propria frequently
thickened [8, 15, 59, 95, 101];
mesenteric (i.e. jejunal)
lymphadenomegaly frequent
[95]; gastrointestinal
intramural masses rare [75];
stratification, architecture and
motility normal to modified [95]
Muscularis propria frequently
thickened in eosinophilic enteritis
(EE), and occasionally in lymphoplasmacytic
enteritis (LPE) [15, 78, 84, 95, 101];
mesenteric lymphadenomegaly
frequent [78, 95]; gastrointestinal
intramural masses rare [75];
stratification architecture,
and motility normal to modified [95]
Histological features
and immunohistochemistry
Diffuse infiltration
by monomorphic
neoplastic T-cells [6, 8]
Polymorphic inflammatory infiltrate
of lymphocytes, plasma cells (LPE),
neutrophils, eosinophils
(EE), and macrophages [75, 84, 174]
Clonality test Clonal population of
lymphocytes [10, 15, 62, 95]
Polyclonal population
of lymphocytes [10, 15, 95, 174]
NA not available
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the two conditions comparing aetiology, signalment,
clinical signs, and diagnosis.
Treatment
Chemotherapy
Systemic chemotherapy is generally considered to be the
most effective treatment for AL [2, 39], although proto-
cols have not been frequently described [3]. Compared
with other forms of lymphoma, less intensive chemo-
therapy protocols have been suggested [20], with the
most common protocols involving oral administration of
both glucocorticoids (prednisolone or dexamethasone)
and chlorambucil (Table 5) [20, 59, 72, 97]. The optimal
duration of chemotherapy has not been determined and,
because these drugs are well tolerated, treatment is
rarely discontinued. In one study involving 56 cases of
feline small cell lymphomas (37 AL), all cats were
treated with glucocorticoid and chlorambucil with dis-
continuation of treatment recommended at one year if
complete clinical response was documented. Subsequent
reintroduction as rescue chemotherapy appears to be
just as effective as continued administration in cats and
median overall survival times for cats with AL was
1148 days [96].
Rescue protocol
Other chemotherapy protocols can be used if relapse is
experienced, with examples including: cyclophospha-
mide and prednisolone; cyclophosphamide, vincristine
and prednisolone (COP protocol) +/− L-asparaginase
and doxorubicin (VELCAP-C); lomustine PO with or
without corticosteroid [2, 4, 7, 39, 82]. In the study of
Stein et al., involving 28 cats diagnosed with LGAL and
treated with a combination of chlorambucil and gluco-
corticoids, seven of the nine cats with relapsed disease
were treated with a rescue protocol of cyclophosphamide
(PO 200–250 mg/m2 given on days 1 and 3 q2wk) and
prednisolone (5 mg q48h). The response rate was 100%
based on resolution of clinical signs and normal abdom-
inal palpation. Three cats died of unrelated diseases,
three cats were lost to follow-up, and the final cat re-
lapsed 241 days after starting the rescue protocol [97].
However, to the authors’ knowledge, there are no studies
comparing the outcome of cats with LGAL treated by
other recue protocols, mainly because studies include all
subtypes of AL. Interestingly, one cat in the study of
Lingard et al. did not respond to a multi-agent protocol,
but entered long-term remission with oral administra-
tion of prednisolone and chlorambucil, suggesting that
LGAL may be sensitive to alkylating agents such as
Chlorambucil [59].
Surgical resection
Given that LGAL lesions are usually diffuse, surgical re-
section is rarely indicated as a means of managing the
disease. In rare cases where an obstructive mass lesion is
present, partial resection could be considered as part of
the treatment [107, 138]. The main disadvantage of sur-
gical resection is the risk of post-operative complications
[76, 139], which can include dehiscence, typically occur-
ring between 2 and 5 days after surgery [75]. Neverthe-
less, in one study involving 20 cases of intermediate
−/high-grade AL where surgical resection of disease was
performed prior to CHOP-based chemotherapy, no
post-operative surgical complication occurred [138].
Cats with AL do not appear to be at high risk of
post-operative complications after full-thickness gastro-
intestinal surgery [138, 139].
Adjuvant therapy
In addition to chemotherapy, a highly digestible diet is
typically recommended, with appetite stimulants (most
Table 5 Description of chemotherapy protocols based on Chlorambucil (PO) and Prednisolone (PO) administration in low-grade
alimentary lymphoma (LGAL) [20, 59, 72, 97]
Study Stein et al. [97] Lingard et al. [59] Kiselow et al. [72] Fondacaro et al. [20]
Number of cases 28 12 41 29
Prednisolone 1–2 mg/kg PO q24hb 3 mg/kg PO q24h,
tapering
to 1–2 mg/kg once
in remission
5 mg/cat PO q12-24 h 10 mg/cat PO/cat/day
Chlorambucil 20 mg/m2 PO q2wkc 15 mg/m2 PO q24h
for 4d q3wk
2 mg/cat PO q48h 15 mg/m2 PO q24h
for 4d q3wkd
Number responding 27 (96%) NA 37 (95%) NA
Complete remission rate NA NA 22 (56%) 20 (69%)
Median remission timea 786 days 505 days 897 days 615 days
Median survival time NA 513 days 704 days 510 days
NA not available
aRemission time in days for cats displaying a complete response; bTwo cats received dexamethasone, initially at immunosuppressive dosages and then at dosages
that were gradually tapered over the course of 3 weeks; cBecause of client preference, two cats were switched to 20 mg/m2 chlorambucil orally q3wk; dTwelve of
the 20 cats that achieved CR received cyclophosphamide 225 mg/m2 PO q3wk, once they were out of remission
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commonly mirtazapine 3.75 mg/cat PO, every 3 days)
used in cats with partial or complete anorexia [75, 107].
A recent paper described the use of growth hormone se-
cretagogues, such as capromorelin, for appetite stimula-
tion in cats [140]. Capromorelin was already shown to
increase food intake or weight gain in dogs and humans
[141, 142]. Treatment with capromorelin at 6 mg/kg
once daily for 91 days in 8 healthy laboratory cats re-
sulted in increased body weight and a greater mean food
consumption compared to the 4 placebo-treated cats.
The optimal clinical dose of capromorelin in cats has yet
to be confirmed, although no serious adverse events
were observed in the recent study [140].
Cats with concurrent hypocobalaminaemia are usually
treated with supplemental cobalamin (e.g. 250 μg/cat SC
once weekly for at least 6 weeks), although there is no
clear consensus on doses and duration [72, 82, 86, 87].
The clinical benefits of prebiotics, probiotics and
gluten-free diet as adjuvant therapies in LGAL have not
yet been proved and need to be investigated in rando-
mised studies [107].
Prognosis
In contrast to HGAL and LGLL, prognosis for LGAL is
good with a high remission rate when the treatment is
carried out over several months or years [13, 14, 59, 75,
82]. Most causes of death include relapse, comorbidities,
or euthanasia in accordance with the owner’s request
[20, 59, 107]. Initial response to chemotherapy seems to
be the most significant prognostic indicator [5, 20, 40,
143–145], with the presence of lethargy, vomiting and
anorexia at initial diagnosis also considered to be nega-
tive prognosis factors [59]. However, no association has
been observed between the response to LGAL treatment
and a variety of other factors including: age, weight, sex,
type and duration of clinical signs, presence of extra in-
testinal lesions, and decreased concentrations of folate,
cobalamin and plasma total protein [38, 72, 75, 120]. It
remains unclear as to whether, in the long-term, LGAL
can progress to more aggressive forms of AL.
Discussion
A model for human indolent T-cell lymphoproliferative
disorders of the gastrointestinal tract?
Within the “One-Health” concept, the domestic cat is
considered to be a good model for comparative biomed-
ical research. Indeed, naturally-occurring feline cancers
offer opportunities for comparative and translational ad-
vances that could be of mutual benefit for both human
and veterinary oncology [146–148]. Therefore, as well as
improving diagnostic tools for feline LGAL, identifying
aetiological factors in cats may ultimately be beneficial
to human patients with indolent digestive lymphoma.
Table 6 Pathological features of human digestive T-cell lymphoma [25, 153, 164, 165, 175, 176]
Clinical features Histology Immunophenotype Outcome
Indolent digestive T-cell lymphoproliferative disease Diarrhoea,
abdominal pain
- Crypt hyperplasia, variable
degrees of villous atrophy
- Non-destructive superficial
infiltrate of small uniform
T-cells mostly lamina
propria-based
- Infiltration into submucosa
observed in some cases
- No evident major
epitheliotropism
CD3+, CD8+ or CD4+,
CD2+, CD5+/−, CD7+/−,
CD30-, CD56-, TCRαβ+
Indolent chronic
relapsing course
Enteropathy associated T-cell lymphoma (EATL) Overt or silent
gluten-sensitive
enteropathy
- Crypt hyperplasia,
villous atrophy
- Pleomorphic medium- to
large-sized neoplastic
lymphocytes with
transmural infiltration
- Presence of other mixed
inflammatory cells such
as histiocytes and eosinophils
- Intraepithelial lymphocytosis
present in non-tumoral
mucosa and in epithelium
distant from the main mass
CD3+, CD5-, CD8−/+,
CD56-, CD103+, often
CD30+, cytotoxic
phenotype +/−,
TCR αβ + (usually)
Aggressive
Monomorphic epitheliotropic T-cell lymphoma Occurs without
a history of
coeliac disease
- No crypt hyperplasia,
possible villous atrophy
- Monomorphic infiltrate
with epitheliotropism
- Transmural infiltration
- No associated
inflammatory background
CD3+, CD5-, CD4-,
CD8+, CD56+, cytotoxic
phenotype, CD30-,
TCR γδ + (usually)
Aggressive
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Human indolent T-cell lymphoproliferative diseases of the
gastrointestinal tract
Human primary gastrointestinal lymphomas are very
rare, accounting for less than 5% of all non-Hodgkin
lymphomas (NHL) yet representing the largest group of
primary extranodal NHL, with approximately 25% of
cases occurring in the gastrointestinal tract [19, 149].
They are predominantly located in the stomach (50–
60%), whereas intestinal lymphomas are less common
and affect the small and large bowel in 20–30% and 10–
20% of cases, respectively [150–152]. Amongst primary
intestinal T and NK-cell lymphoma, indolent intestinal
T-cell lymphomas are newly described forms of
low-grade, diffusely infiltrating T-cell lymphomas.
Indolent T-cell lymphoproliferative diseases (LPD) of
the gastrointestinal tract have been described as clonal
T-cell proliferations, with an indolent clinical course
after long-term monitoring [153]. These diseases are
very rare and have only been reported as sporadic cases
or in small case series [154–161]. Patients commonly
present with chronic diarrhoea, weight loss, malnutri-
tion, abdominal pain or rectal bleeding. In some cases,
autoimmune diseases may develop, for example coeliac
disease or autoimmune enteropathy [154–156, 162].
Macroscopic findings include villous atrophy, mucosal
erythema, erosions or small ulcerations and, occasion-
ally, small polyps without mass lesions [149]. Patients
usually have multiple lesions along the gastrointestinal
tract, most commonly in the small intestine and colon
[149]. On histological examination, the lamina propria is
densely infiltrated with a monomorphic population of
small lymphoid cells. Severe intestinal villous atrophy,
caused by the lamina propria infiltration, is commonly
observed, but there is usually no evidence of epithelial
destruction [149]. Tumour cells are CD3+, either CD4+
(more commonly) or CD8+, or in rare instances CD4−/
CD8−, whilst those expressing CD8 have a cytotoxic pro-
file (TIA1+, granzyme B±) [153, 154, 156, 163]. Usually,
CD56, CD30, CD103 and Epstein-Barr virus are not de-
tected, whilst the Ki67 proliferation index is low e.g. in
the range of 5–10% [153, 154, 156, 163]. Tumour cells
display TCRγ or β gene rearrangements and the
TCRβ-chain is expressed on the surface in most cases,
most notably in CD4+ cases [153, 154, 156, 163].
The condition is clinically indolent, and most patients
are still alive with a persistent disease after several years
of follow-up [153, 154, 156, 163]. Nevertheless, three
cases have been reported where patients died from ag-
gressive T-cell lymphoma several years after being diag-
nosed [154]. In addition, conventional chemotherapy
does not lead to durable clinical and histological re-
sponses in such patients and has been associated with
high toxicity [153, 154, 156, 163].
Little is known about the mechanisms involved in the
pathogenesis of indolent LPD of the gastrointestinal
tract. Given the coexistence of autoimmune or inflam-
matory diseases, it has been speculated that immune
dysregulation plays a role in disease pathogenesis [153,
154, 156]. Environmental factors such as diet or infec-
tious agents (e.g. viruses, bacteria) could also be involved
in the development of this disease. Human herpes virus
6 (HHV6) was detected in the small intestinal biopsies
of one patient by PCR analysis and two patients had
positive serology for human T-lymphotropic virus type 1
(HTLV1) at the time of diagnosis, but with no evidence
of viral integration in the intestinal biopsies [156]. In
addition, no specific disease-associated chromosomal or
genetic alterations have been uncovered so far. To date,
the origin of indolent digestive T-cell LPDs remains un-
known. In a subset of cases, there is expression of
CD103, suggesting that such LPDs originate from a
Table 7 Comparison of feline low-grade alimentary lymphoma
(LGAL) and human indolent digestive T-cell lymphoproliferative
disease (LPD)
Data Feline LGAL Human indolent digestive T-cell
LPD
Epidemiology Frequent, increasing
prevalence over
the last decade
Very rare
Clinical signs Non-specific weight
loss, vomiting,
anorexia, diarrhoea
Non-specific weight l
oss, diarrhoea, abdominal
pain, digestive bleeding,
malnutrition
Gastrointestinal
localisation
Multiple lesions
affecting all the
gastrointestinal
tract; small intestine
as main involvement
Multiple lesions affecting
all the gastrointestinal
tract; small intestine
as main involvement
Histology Monomorphic
population of small-
to intermediate-sized
T-lymphocytes;
infiltration of neoplastic
T-cells in villi and lamina
propria; moderate
villous atrophy;
crypt hyperplasia
Monomorphic population
of small- to intermediate-sized
T-lymphocytes
Infiltration of neoplastic
T-cells in villi and lamina
propria; villous atrophy
(often severe);
crypt hyperplasia;
erythema of the
mucosa; ulcers;
mucosal nodularity
Immunophenotyping CD3+ CD3+ CD4+ (frequent)
or CD8+ or CD4-/CD8- (rare)
Clonality pattern Clonal or oligoclonal
TCRγ rearrangement
Clonal or oligoclonal
TCRγ rearrangement
Main differential
diagnosis
Inflammatory bowel
disease
Refractory coeliac
disease, autoimmune
enteropathy
Outcome Indolent evolution Indolent evolution
Median survival time of
2 years
Persistent disease
at a median
follow up of 5 years
Treatment No gold standard No gold standard
Chlorambucil and
steroids most common
“Watch and wait”
strategy, immunosuppressive
agents, chemotherapy
(CHOP regimen),
anti CD52 monoclonal antibody
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mucosal T-cell precursor, although further characterisa-
tion would be required [164].
Comparison of feline low-grade alimentary lymphoma with
human digestive T-cell lymphoma
The main characteristics of each subtype of human di-
gestive T-cell lymphoma are presented in Table 6.
Although it has been suggested that the feline LGAL
most closely resembles enteropathy-associated T-cell
lymphoma (EATL; previously designated type I EATL)
or monomorphic epitheliotropic intestinal T-cell lymph-
oma (MEITL; previously designated type II EATL) [6],
the authors contend that it has more characteristics in
common with indolent digestive T-cell LPDs in humans,
according to the latest WHO classification [165]. Clin-
ical, histological and phenotypic features of feline LGAL
and human indolent digestive T-cell LPDs are compared
in Table 7 and Fig. 5 [149, 153–156, 159].
As previously mentioned, the pathogenesis of hu-
man indolent digestive T-cell LPD is poorly under-
stood and the rarity of the disease in humans is the
major factor limiting the identification of putative
oncogenic events. In contrast, the fact that feline
LGAL is more common suggests that it might be a
suitable animal model for the human condition, to
elucidate some of the pathogenic mechanisms under-
lying human indolent T-cell LPD of the gastrointes-
tinal tract. Through domestication, humans, dogs and
cats share a common environment and therefore dis-
play common signatures of coevolution, including epi-
genetic markers [166, 167]. This might explain why
humans and pets are affected by closely-related dis-
eases resulting from variations in genes expression al-
tering conserved functional pathways [168]. The
depth and quality of medical phenotyping in pets, as-
sociated with their facilitating haplotype structure and
the development of genomics tools make them the
most valuable mammalian models in medical genetics,
including comparative oncology [169]. In the last two
decades, dozens of disease-causing variants have been
successfully identified in pets, most of them directly
informative for humans [168]. Therefore, there is
great potential for future research into feline LGAL
not only to benefit cats, but also humans.
Conclusion
Feline low-grade alimentary lymphoma (LGAL) is the
most frequent intestinal neoplasm and is characterised
Fig. 5 Comparison of histological and immunohistochemical features of feline low-grade alimentary lymphoma (LGAL) and human indolent
digestive T-cell lymphoproliferative disease (LPD). Top Panel: Human indolent CD4+ T-cell lymphoproliferative disease of the gastrointestinal tract.
Biopsies of the antrum (a, b, c) and duodenum (d, e, f) show important CD3+ (b and e) and CD4+ (c and f) lymphoid infiltrate into the lamina
propria (asterisk), mostly composed by small lymphocytes. Epitheliotropism is mostly absent, with however focal exceptions such as small CD4+
T-cells localized here in the duodenal epithelium (arrow). Bottom Panel: Feline T-cell low-grade alimentary lymphoma. Biopsies of the jejunum
show epitheliotropic lymphocytic infiltrate involving the lamina propria (g), exhibiting a CD3+ phenotype (h)
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by diffuse infiltration of monomorphic neoplastic T-cells
in the gastro-intestinal tract. However, diagnosis is still a
major challenge, mainly the difficulty in differentiate the
condition from inflammatory bowel disease. That said,
developments in immunohistochemical analysis and
clonality testing have improved the confidence of clini-
cians in obtaining a correct diagnosis. The pathophysi-
ology of feline LGAL still needs to be elucidated, not
least the putative roles of infectious agents, environmen-
tal factors as well as genetic events. The most common
therapeutic strategy is combination treatment with pred-
nisolone and chlorambucil, and prolonged remission can
often be achieved. However, different variations of this
therapeutic strategy exist, and standardisation is needed.
Importantly, feline LGAL could be considered to be a
potential animal model for human indolent digestive
T-cell lymphoproliferative disease. By exploring the
pathogenetic mechanisms involved in feline LGAL, it
should be possible to improve understanding of the hu-
man disease, identify diagnostic and prognostic markers
and develop effective therapeutic regimens. More
broadly, such an approach could provide insights into
the host-pathogen interactions occurring in the gastro-
intestinal tract and fundamental processes involved in
physiological gut immunology.
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